A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing it significantly reduces risk of progression in CLL compared w
As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just in blood cancer, but in previously overlooked diseases such as sickle cell anaemi